| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥268.4B | ¥236.1B | +13.7% |
| Operating Income | ¥-34.8B | ¥14.0B | -89.3% |
| Profit Before Tax | ¥-46.5B | ¥2.4B | -98.1% |
| Net Income | ¥-73.2B | ¥-0.1B | -81211.1% |
| ROE | -14.2% | -0.0% | - |
FY2025 full-year results: Revenue 268.4B yen (YoY +13.7%), Operating Loss 34.8B yen (from 14.0B yen profit in prior year, YoY -89.3%), Ordinary Loss 46.5B yen, Net Loss attributable to owners 44.1B yen (prior year 11.0B yen profit). The company experienced a significant deterioration in profitability despite revenue growth, transitioning from operating profit to substantial operating loss. Gross profit margin remained high at 74.5%, but SG&A expenses surged to 190.0B yen (70.8% of revenue), overwhelming revenue growth. Operating cash flow was negative at 24.1B yen, resulting in free cash flow of negative 29.4B yen. Cash and equivalents stood at 211.0B yen, providing adequate liquidity cushion despite deteriorated operating performance.
Revenue increased 32.3B yen or 13.7% YoY to 268.4B yen, driven by growth in both pharmaceutical and medical device segments. Pharmaceutical segment revenue grew 8.6B yen to 191.6B yen (+4.7% YoY), while medical device segment expanded significantly by 23.7B yen to 76.8B yen (+44.7% YoY). Geographic expansion contributed to growth, with China revenue increasing from 170.9B yen to 185.0B yen (+8.3%) and US revenue growing from 50.5B yen to 75.3B yen (+49.2%). Key customer Sinopharm increased purchases by 16.1B yen to 67.4B yen, while new major customer New Horizon Medical contributed 33.2B yen in the medical device segment. Product-wise, flagship drug Etuary maintained stable sales at 157.9B yen, while biomaterial products surged from 51.7B yen to 75.7B yen (+46.4%).
Operating profit deteriorated dramatically from 14.0B yen profit to 34.8B yen loss, representing a negative swing of 48.8B yen. Gross profit increased 18.2B yen to 199.9B yen, but SG&A expenses increased 32.3B yen to 190.0B yen, including significant stock compensation expense of 22.1B yen recorded in the period. R&D expenses also increased from 28.1B yen to 33.0B yen (+17.4%), reflecting continued investment in drug development. Other expenses rose substantially from 4.9B yen to 17.0B yen, including non-recurring factors. The pharmaceutical segment reported operating loss of 40.1B yen (from 3.7B yen profit), while medical device segment maintained profitability at 5.3B yen.
The gap between operating loss of 34.8B yen and net loss of 73.2B yen (38.4B yen difference) primarily reflects net financial costs of 11.7B yen (financial expenses 17.5B yen minus financial income 5.8B yen) and income tax expense of 26.7B yen despite pre-tax loss, suggesting deferred tax adjustments or non-deductible expenses. This represents a revenue up/profit down pattern with structural profitability deterioration.
The pharmaceutical segment generated revenue of 191.6B yen (71.4% of total) but reported operating loss of 40.1B yen, representing a negative operating margin of 20.9%. This core business experienced significant margin compression from 2.0% profit margin in prior year. The medical device segment contributed revenue of 76.8B yen (28.6% of total) with operating profit of 5.3B yen, maintaining a positive operating margin of 6.9%, improved from 19.4% in prior year despite the lower margin percentage. The pharmaceutical segment remains the core business by revenue contribution but has become a substantial drag on consolidated profitability. The sharp contrast between segments indicates that pharmaceutical operations require urgent restructuring, while medical device operations demonstrate relatively stable execution despite rapid revenue expansion. The 26.8 percentage point margin difference between segments highlights operational execution challenges concentrated in the pharmaceutical business.
[Profitability] ROE negative 10.2% (deteriorated from positive 3.0% YoY), operating margin negative 13.0% (deteriorated from positive 5.9% YoY by 18.9pt), net profit margin negative 27.3%. Gross profit margin 74.5% (prior year 76.4%, declined 1.9pt). R&D intensity 12.3% of revenue. [Cash Quality] Cash and equivalents 211.0B yen increased from 101.2B yen, providing coverage of 1.6x against total current liabilities of 97.6B yen. Operating cash flow negative 24.1B yen with operating CF to net income ratio of 0.33, indicating weak cash conversion. [Investment Efficiency] Total asset turnover 0.35 (prior year 0.35), inventory turnover 1.8x with days inventory outstanding of 200 days (prior year 165 days, deteriorated by 35 days), accounts receivable days sales outstanding 110 days (prior year 96 days, deteriorated by 14 days). Cash conversion cycle 224 days. [Financial Health] Equity ratio 59.9% (prior year 55.2%, improved 4.7pt), current ratio 417.2% (strong liquidity position), debt-to-equity ratio 0.06 (minimal leverage), net debt negative 179.9B yen indicating net cash position.
Operating cash flow was negative 24.1B yen, improving from negative 31.6B yen in prior year but remaining in deficit territory. The operating CF before working capital changes was negative 18.9B yen, with additional cash outflows from working capital deterioration including inventory increase of 9.9B yen and accounts payable decrease of 9.1B yen, partially offset by other operating adjustments of 10.5B yen. Non-cash items included depreciation and amortization of 11.4B yen and stock compensation expense of 22.1B yen. Income taxes paid totaled 7.6B yen and interest paid 1.5B yen. Investing cash flow was negative 5.4B yen, primarily consisting of capital expenditures of 3.3B yen and intangible asset acquisitions of 12.2B yen, with subsidiary acquisition outflow of 12.0B yen, offset by deposit decrease inflow of 6.8B yen. Financing cash flow was strongly positive at 137.4B yen, driven by equity issuance proceeds of 125.9B yen (including 89.6B yen from new share issuance and 8.5B yen from warrant exercises) and minority interest capital injection of 32.7B yen, partially offset by short-term borrowing repayment of 32.5B yen. Free cash flow remained negative at 29.4B yen. The substantial equity financing significantly strengthened the balance sheet, with cash position increasing 109.9B yen to 211.0B yen despite negative operating and investing cash flows.
Operating loss of 34.8B yen versus ordinary loss of 46.5B yen indicates net non-operating expense contribution of approximately 11.7B yen. Non-operating items comprise financial expenses of 17.5B yen exceeding financial income of 5.8B yen, other expenses of 17.0B yen exceeding other income of 5.3B yen, and minimal equity method income of 0.1B yen. Non-operating expense represents 4.4% of revenue as a net burden. The significant stock compensation expense of 22.1B yen recorded within operating expenses represents a non-cash charge that partially explains the divergence between reported loss and cash flow. Income tax expense of 26.7B yen recorded against pre-tax loss of 46.5B yen suggests deferred tax asset derecognition or valuation allowance adjustment, evidenced by deferred tax assets declining from 22.3B yen to 3.5B yen. Operating cash flow at negative 24.1B yen against net loss of 73.2B yen yields an operating CF to net income ratio of 0.33, indicating poor cash conversion quality. Working capital deterioration with inventory increasing 48.4% and receivables increasing 29.2% while payables decreased 29.3% further weakens earnings quality. The combination of negative operating cash flow, substantial non-cash charges, and working capital consumption indicates structural earnings quality concerns requiring operational improvement.
Annual dividend is zero yen for both FY2024 and FY2025, with company forecasting zero dividend for FY2026. Payout ratio is not applicable due to net loss position. No share repurchase activity was recorded (share repurchases in cash flow statement: 0.0B yen). Total shareholder return ratio is zero. The suspension of dividends reflects the company's loss-making position and capital preservation priority following significant equity dilution through new share issuances totaling approximately 89.6B yen during the fiscal year.
Pharmaceutical segment profitability crisis: Operating loss of 40.1B yen in the core pharmaceutical segment representing 71% of revenue indicates fundamental business model stress. Segment margin deteriorated 22.9 percentage points from positive 2.0% to negative 20.9%, driven by SG&A expense surge and potential drug development setbacks. Without urgent cost restructuring or pipeline success, losses may persist and accelerate equity erosion.
Working capital deterioration and cash consumption: Cash conversion cycle extended to 224 days with inventory days outstanding increasing 35 days to 200 days and receivables collection extending 14 days to 110 days. Negative operating cash flow of 24.1B yen combined with negative free cash flow of 29.4B yen indicates unsustainable cash consumption. Despite current cash reserves of 211.0B yen, continued operational cash burn at current rate would deplete liquidity within 7-8 years absent improvement.
Customer and geographic concentration exposure: Top customer Sinopharm represents 25.1% of total revenue (67.4B yen), while top 5 customers comprise approximately 49% of revenue. Geographic concentration in China (68.9% of revenue) and dependence on single-payer/state-affiliated healthcare customers creates regulatory, pricing, and political risk exposure that could materially impact revenues if relationship dynamics or market access conditions deteriorate.
[Industry Position] (Reference - Proprietary Analysis)
The company's profitability metrics significantly underperform pharmaceutical/biotechnology industry standards. ROE of negative 10.2% substantially trails the sector, where profitable companies typically maintain ROE in the range of 8-15% for mid-sized pharmaceutical firms. Operating margin of negative 13.0% compares unfavorably to industry median operating margins of 10-20% for established pharmaceutical companies, reflecting severe operational efficiency challenges. The company's equity ratio of 59.9% is moderately healthy and falls within acceptable industry norms of 40-70%, though the ratio has been artificially supported by significant equity capital raises totaling 125.9B yen during the period. R&D intensity of 12.3% of revenue aligns with pharmaceutical industry standards where R&D typically represents 10-20% of revenue depending on development stage and pipeline maturity. The gross profit margin of 74.5% is competitive within pharmaceutical and medical device sectors, suggesting that margin compression originates from operating expense structure rather than pricing or production efficiency. Revenue growth of 13.7% exceeds typical mature pharmaceutical company growth rates of 3-8%, indicating the company is in a growth investment phase, though this growth is not yet translating to profitability. The company's positioning reflects a transition-phase biopharmaceutical company with strong revenue momentum and reasonable balance sheet, but with acute profitability challenges requiring operational restructuring to achieve industry-standard margins.
(Industry: Pharmaceutical and Medical Device, Reference data: Proprietary analysis of comparable companies)
Significant operational restructuring imperative amid revenue growth: The company achieved 13.7% revenue growth to 268.4B yen with particularly strong performance in medical devices (+44.7%) and international markets, yet simultaneously recorded operating loss of 34.8B yen and net loss of 73.2B yen. This divergence between top-line expansion and bottom-line deterioration indicates fundamental cost structure misalignment. SG&A expenses of 190.0B yen consuming 70.8% of revenue and the pharmaceutical segment's negative 20.9% operating margin signal urgent need for cost optimization, operational efficiency improvements, and potential business model recalibration to convert revenue scale into sustainable profitability.
Balance sheet fortified through equity financing but working capital efficiency declining: The company raised substantial equity capital of 125.9B yen during the period, strengthening cash position to 211.0B yen and equity ratio to 59.9%, providing adequate runway to fund operations and strategic initiatives. However, working capital management deteriorated significantly with cash conversion cycle extending to 224 days, inventory increasing 48.4%, and receivables growing 29.2% while operating cash flow remained negative at 24.1B yen. This indicates that revenue growth is capital-intensive and cash-consumptive, requiring focused attention on inventory optimization, receivables collection acceleration, and operational cash generation to avoid continued dilutive financing needs.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.